A. Golenkov

Phase 3 Randomized Trial of Fludarabine/Cyclophosphamide Chemotherapy with or without Oblimersen Sodium (Bcl-2 Antisense; Genasense; G3139) for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL).

R. Bociek, A. Chanan-Khan, K. Rai, 2004 .

A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older.

W. Jędrzejczak, H. Dombret, G. Martinelli, 2007, Blood.

Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia.

K. Rai, S. O'brien, A. Turkina, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

ASSAY OF IMMUNOGLOBULIN FREE LIGHT CHAINS IN THE SERUM FOR EVALUATING CHEMOTHERAPY EFFICACY IN PATIENTS SUFFERING FROM MULTIPLE MYELOMA WITH INTACT MEASURABLE PARAPROTEIN

A. Karaulov, A. Golenkov, Y. Chernykh, 2019, Russian journal of hematology and transfusiology.

Expression levels of the apoptosis genes FAS, TNFR2, TRAIL, DR3 and DR4/5 in patients with newly diagnosed chronic lymphatic leukemia before and after treatment with fludarabine, cyclophosphamide and rituximab (FCR)

M. Baryshnikova, Y. Finashutina, V. Misyurin, 2018, Almanac of Clinical Medicine.

A prospective study of the monitoring of patients with chronic myeloid leukemia upon withdrawal of tyrosine kinase inhibitor therapy

G. Gusarova, A. Sudarikov, V. Savchenko, 2020, Russian journal of hematology and transfusiology.

Efficiency of lenalidomide, bortezomib and prednisone (RVP) in patients with newly diagnosed multiple myeloma

A. Golenkov, Y. Chernykh, T. Mitina, 2019, Oncohematology.